Real-Time PCR / Quantitative PCR
Our scientific team works with you, in a collaborative approach, to develop, optimize, and validate your complex molecular assays using quantitative PCR (qPCR) to support your preclinical needs. Our experts are specialized in biodistribution and gene expression studies.
Take a look inside our PCR lab.
Schedule a conversation with one of our experts to discuss our PCR platform.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Have 5 minutes? Take a look at these scientific publications:
Driving Simulation – An Indispensable Tool for Clinical Trials
Altasciences Expands Ligand Binding Laboratory to Meet High Demand for Bioanalytical Solutions
Laval, Quebec, November 23, 2021 — Altasciences, a leading drug development solution company, announced today the completion of a second expansion of their ligand binding laboratory to meet the high demand for quality bioanalytical services. The GLP, GCP laboratory was enlarged to include 52 benches for sample analysis, an enhanced space for cell culture and flow cytometry services, additional extraction rooms for handling all types of tissue matrices, a dedicated CL2 room for handling samples and RG2 material, a balance room for critical reagent and solution preparation, and an extraction space for an additional 50 analysts.
“At Altasciences’ One Laboratory Sciences, we accelerate our clients’ programs by seamlessly integrating our new state-of-the-art bioanalytical lab with our preclinical and clinical studies,” added Dr. Lynne Le Sauteur, Vice President, Laboratory Sciences.
With this expansion, Altasciences’ ligand binding assay tripled its square footage and will add to its employee base. Altasciences’ goal is to offer clients the opportunity to leverage the significant knowledge and industry experience of our team of scientific experts to develop strategic bioanalytical testing plans to complement their drug development programs.
“Our growing state-of-the-art laboratory will further expand our breadth of expertise and services for ligand binding assays, cell-based assays, flow cytometry, and other specialty assays to support biologics and oligonucleotide drug development,” says Dr. Danielle Salha, Senior Director, Immunochemistry & Immunology, Ligand Binding Assays.
Altasciences uses innovative and cost-effective approaches to develop or customize ligand binding assays for the quantitative determination of biologics and small-molecule therapeutic products. Altasciences continues to expand its immunogenicity, PK, oligonucleotide, and biomarker testing to its already robust preclinical and clinical study and bioanalysis testing capabilities.
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com
How to Complete Nonhuman Primate Safety Testing Up to Three Months Faster
Are you struggling to schedule safety testing with nonhuman primates (NHP)? At Altasciences, we have secured a supply of research animals, making our study start times for NHP studies one to three months faster than industry norms.
What we do to ensure NHP supply for our clients:
- Keep dedicated and diversified Cynomolgus monkey supply agreements in place to allow for faster start-up timelines
- Continuously maintain and backfill a population of several hundred naïve NHPs at our preclinical facility
What this means for you:
- Schedule newly contracted NHP studies to start in late Q1 / early Q2 2022
At Altasciences, we do not rely on a single-source NHP supply chain. We remove the stress of sourcing research animals so that you can start your studies faster.
Contact us to schedule your NHP studies today.
You may also be interested in the following:
- Podcasts:
- Fact Sheet: Biologics Safety Assessment Capabilities
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated, synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
How to Overcome Formulation Challenges in Drug Development
Over 80% of drugs will fail during clinical development ― formulation challenges and lack of efficacy being the major causes.
How do we overcome these challenges?
Altasciences’ integrated approach combines formulation development for preclinical and clinical studies, analytical assay development and validation, excipient screening, GMP manufacturing, as well as finished product and release testing ― seamlessly transitioning your project from R&D to clinical supply.
Our expertise includes:
- Scale-up and clinical/commercial manufacturing of drug products with complex formulations
- Developing and manufacturing of liquid-filled, hard-shell capsules required for poorly soluble molecules and difficult formulations
- Handling of potent compounds and controlled substances (Schedules I-V), with expertise in cannabinoids and psychedelic/hallucinogenic drugs
- Manufacturing of wet nanomilled suspensions with scales up to 2,000 L
By partnering with Altasciences, you will:
- Reduce your timelines
- Improve and accelerate critical decision making
- Minimize risk of product failure
Trust your drug product development to a reliable, experienced CDMO.
Contact us.
You may also be interested in the following:
Clinical Sample Kit Management
From trial sites to our labs, Altasciences’ Material Management Team has over 25 years of experience supporting clinical trials around the globe. We make it easy with efficient collection, preparation and shipment of clinical samples.
Each kit is adapted to your specific study needs, and allows for the storage and shipping of different matrices, such as plasma, urine, serum, and whole blood.
Download our fact sheet to learn more about our capability or
send us an e-mail and we will connect you with an expert within 24 hours.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
You may also be interested in the following:
Webpages:
Fact Sheet:
Psychedelics — A New Era of Modern Medicine
The potential use of psychedelics for the treatment of various CNS indications is filling the drug development pipeline. Researchers in the field are examining modified chemical structures and analogs to psychedelics, to demonstrate efficacy and mitigate potential side effects.
In this podcast, Altasciences’ and DevelRx’s scientific experts examine the preclinical, clinical, and regulatory requirements and strategies that second-generation psychedelics may utilize to differentiate their pharmacological profile. We examine how to demonstrate efficacy and generate safety data that may distinguish psychedelics from first generation candidates.
Speak with an expert about your research needs.
You may also be interested in the following:
- Blog: Clinical Applications of Hallucinogens, Dissociatives, and other Schedule I Drugs
- Webinar: Navigating Early Phase CNS-Active Drug Development with Dr. Beatrice Setnik, CSO
- The Altascientist: CNS, Hallucinogens, and Other Schedule I Drugs
- Fact Sheet: Central Nervous System Capabilities
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Nonclinical Assessment Planning Guide